Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 1.00 |
| ▸ | HTR1B | P28222 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 1.00 |
| ▸ | HTR5A | P47898 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 1.00 |
| ▸ | HTR3B | O95264 | 3/20 | 1.00 |
| ▸ | HTR1E | P28566 | 3/20 | 1.00 |
| ▸ | HTR1F | P30939 | 3/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 3/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.65 |
| ▸ | MPO | P05164 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633037 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31579279 | 0.90 | HTR1D (0.82) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31579517 | 0.87 | HTR1D (0.78) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31579547 | 0.86 | HTR1D (0.76) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31579554 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31579687 | 0.85 | HTR1D (0.73) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL30831820 | 0.83 | HTR1D (0.71) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL30831814 | 0.83 | HTR1D (0.71) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL8868722 | 0.83 | HTR1D (0.71) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL31176578 | 0.82 | HTR1D (0.69) | HTR1DHTR1BHTR1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | Convergent Health Sciences LLC: (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR1D 7/4885HTR1B 4/4885HTR1A 5/4885 |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | PLCB1, PHKG1, PLCB3 | HTR1D 144/4885HTR1B 8/4885HTR1A 91/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR1D 11/4885HTR1B 10/4885HTR1A 5/4885 |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR1D 13/4885HTR1B 4/4885HTR1A 5/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR1D 12/4885HTR1B 7/4885HTR1A 1/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR1D 33/4885HTR1B 10/4885HTR1A 9/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR1D 18/4885HTR1B 8/4885HTR1A 22/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 7/4885HTR1B 1/4885HTR1A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.